STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [Form 4] HALOZYME THERAPEUTICS, INC. Insider Trading Activity

Form 4: LaBrosse Nicole reports multiple insider transactions in HALO

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LaBrosse Nicole reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 60,440 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 5,329 shares.

Positive

  • None.

Negative

  • None.
Insider LaBrosse Nicole
Role SVP, CHIEF FINANCIAL OFFICER
Type Security Shares Price Value
Exercise Restricted Stock Units 5,093 $0.00 --
Exercise Restricted Stock Units 5,329 $0.00 --
Exercise Performance Stock Units 13,351 $0.00 --
Exercise Common Stock 5,093 $0.00 --
Tax Withholding Common Stock 2,747 $79.44 $218K
Exercise Common Stock 5,329 $0.00 --
Tax Withholding Common Stock 2,874 $79.44 $228K
Exercise Common Stock 13,351 $0.00 --
Tax Withholding Common Stock 7,273 $79.44 $578K
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Performance Stock Units — 0 shares (Direct); Common Stock — 27,172 shares (Direct)
Footnotes (1)
  1. The reported disposition of 2,747 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 2,874 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 7,273 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LaBrosse Nicole
(Last) (First) (Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/16/2026 M 5,093 A $0 27,172 D
Common Stock 02/16/2026 F 2,747(1) D $79.44 24,425 D
Common Stock 02/16/2026 M 5,329 A $0 29,754 D
Common Stock 02/16/2026 F 2,874(2) D $79.44 26,880 D
Common Stock 02/16/2026 M 13,351 A $0 40,231 D
Common Stock 02/16/2026 F 7,273(3) D $79.44 32,958 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 02/16/2026 M 5,093 (4) (4) Common Stock 5,093 $0 0 D
Restricted Stock Units $0 02/16/2026 M 5,329 (4) (4) Common Stock 5,329 $0 5,329 D
Performance Stock Units $0 02/16/2026 M 13,351 (5) (5) Common Stock 13,351 $0 0 D
Explanation of Responses:
1. The reported disposition of 2,747 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
2. The reported disposition of 2,874 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
3. The reported disposition of 7,273 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
4. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
5. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Halozyme (HALO) CFO Nicole LaBrosse report in this Form 4?

Halozyme CFO Nicole LaBrosse reported vesting and settlement of restricted and performance stock units into common shares, plus related tax share withholding. These are compensation-related equity events, not discretionary open-market purchases or sales of Halozyme stock.

How many Halozyme (HALO) shares did the CFO acquire from equity awards?

On February 16, 2026, Nicole LaBrosse acquired Halozyme common stock from vesting equity awards, including 5,093, 5,329, and 13,351 shares from restricted and performance stock units. These were derivative conversions at a stated exercise price of $0 per share.

Were any of the Halozyme (HALO) CFO’s transactions open-market sales?

No. The Form 4 labels the disposal transactions with code F, and footnotes state the 2,747, 2,874, and 7,273 shares were withheld by Halozyme solely to satisfy tax withholding obligations, not sold in open-market transactions initiated by the CFO.

At what price were Halozyme (HALO) shares used for tax withholding?

Shares withheld for tax purposes were valued at $79.44 per share. The issuer retained 2,747, 2,874, and 7,273 common shares at this price to cover Nicole LaBrosse’s tax liabilities associated with the vesting of her stock-based compensation awards.

How many Halozyme (HALO) shares does the CFO own after these transactions?

After the February 16, 2026 transactions, Nicole LaBrosse directly owned 32,958 shares of Halozyme common stock. This figure reflects the shares received from vested equity awards net of those withheld by the issuer to satisfy associated tax obligations.

What types of equity awards vested for Halozyme (HALO) CFO Nicole LaBrosse?

The filing shows vesting and settlement of restricted stock units and performance stock units into Halozyme common stock. Footnotes specify these transactions represent the conversion of RSUs and PSUs into shares as part of LaBrosse’s stock-based compensation package.